Biotechnology Equities Movers and Shakers -- Research on ZIOPHARM Oncology, Clovis Oncology, Arrowhead Research, and NPS Pharma
Editor Note: For more information about this release, please scroll to bottom.
Jun 27, 2014, 07:50 ET
LONDON, June 27, 2014 /PRNewswire/ --
On Thursday, June 26, 2014, the NASDAQ Composite ended at 4,379.05, down 0.02%, the Dow Jones Industrial Average finished the day 0.13% lower at 16,846.13, and the S&P 500 closed at 1,957.22, down 0.12%. The losses were broad based as six out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 708.54, up 0.06%, and the index has advanced 3.99% in the last one month. Investor-Edge has initiated coverage on the following equities: ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), Clovis Oncology Inc. (NASDAQ: CLVS), Arrowhead Research Corp. (NASDAQ: ARWR) and NPS Pharmaceuticals Inc. (NASDAQ: NPSP). Free technical research on ZIOP, CLVS, ARWR and NPSP can be downloaded upon signing up at:
On Thursday, ZIOPHARM Oncology Inc.'s stock recorded a trading volume of 1.03 million shares, lower than its three months average volume of 1.08 million shares. The stock finished the day at $4.05, down 5.37%, and registered an intraday range of $4.02 and $4.27. ZIOPHARM Oncology Inc.'s shares have surged 20.54% in the last one month. However, the stock has declined 17.43% in the previous three months and 6.68% on YTD basis. Furthermore, the company's stock is trading above its 50-day and 200-day moving averages. The stock's 200-day moving average of $3.99 is above its 50-day moving average of $3.62. Additionally, shares of the company have a Relative Strength Index (RSI) of 62.89. Sign up today to read free research on ZIOP at:
Shares in Clovis Oncology Inc. fell by 1.05%, to close Thursday's session at $41.56, after oscillating between $41.24 and $42.48. The stock recorded a trading volume of 0.38 million shares, below its three months average volume of 0.97 million shares. Over the last one month and past three months, shares of Clovis Oncology Inc. have lost 27.09% and 46.37%, respectively. Also, from the beginning of 2014, the company's stock has plummeted 31.04%. The stock is trading below its 50-day and 200-day moving averages. The company stock's 200-day moving average of $60.52 is above its 50-day moving average of $49.55. Further, the company's stock has an RSI of 39.91. Sign up today to read free research on CLVS at:
On Thursday, Arrowhead Research Corp.'s stock finished the session 5.96% higher at $14.22. A total of 1.56 million shares were traded, which was below its three months average volume of 2.00 million shares. The stock moved between $13.39 and $14.28 during the session. Over the last one month and since the start of this year, Arrowhead Research Corp.'s shares have gone up 24.85% and 31.06%, respectively. However, the stock has fallen by 13.11% over the past three months. The company's shares are trading above their 50-day and 200-day moving averages. Moreover, the stock's 50-day moving average of $12.44 is greater than its 200-day moving average of $12.21. Shares of Arrowhead Research Corp. have an RSI of 49.13. Sign up today to read free research on ARWR at:
NPS Pharmaceuticals Inc.'s stock fluctuated between $31.75 and $33.07 before ending Thursday's session up 1.04%, at $32.88. The company's stock reported a trading volume of 0.79 million shares, below its three months average volume of 2.50 million shares. Further, NPS Pharmaceuticals Inc.'s stock have rallied 22.69% over the last one month and 17.26% over the past three months. Also, the stock has gained 8.30% on YTD basis. The stock is trading above its 50-day and 200-day moving averages. The stock's 200-day moving average of $30.18 is greater than its 50-day moving average of $29.10. Moreover, shares of the company have an RSI of 52.87. Sign up today to read free research on NPSP at:
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
Share this article